Catalyst International

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Our mission is to partner with our clients to solve complex problems and discover new opportunities, enabling them to make better decisions and achieve superior business performance.

At Catalyst International, we believe that success is defined by the ability of our clients to transform the way they operate and grow. We strive to create lasting change and to be a reliable and trusted partner in achieving our clients’ goals.

Catalyst International has won numerous awards, including being named a “Best Place to Work” by Forbes magazine and one of the “Fastest Growing Companies” by Fortune magazine. The firm has also received awards from the National Association of Consulting Professionals, the Chicago Consulting Association, and the International Business Award for Outstanding Client Service.